Is BridgeBio Pharma Stock a Good Investment?
BridgeBio Pharma Investment Advice | BBIO |
- Examine BridgeBio Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BridgeBio Pharma's leadership team and their track record. Good management can help BridgeBio Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BridgeBio Pharma's business and its evolving consumer preferences.
- Compare BridgeBio Pharma's performance and market position to its competitors. Analyze how BridgeBio Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if BridgeBio Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BridgeBio Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BridgeBio Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BridgeBio Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine BridgeBio Pharma Stock
Researching BridgeBio Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.05. BridgeBio Pharma recorded a loss per share of 2.42. The entity had not issued any dividends in recent years.
To determine if BridgeBio Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BridgeBio Pharma's research are outlined below:
| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| BridgeBio Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (643.2 M) with profit before overhead, payroll, taxes, and interest of 74.21 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (527.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| BridgeBio Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: What is Leerink Partnrs Forecast for BBIO FY2024 Earnings |
BridgeBio Pharma Quarterly Long Term Debt |
|
BridgeBio Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BridgeBio Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BridgeBio Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BridgeBio Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BridgeBio Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-03-02 | 2019-12-31 | -0.7 | -0.62 | 0.08 | 11 | ||
2023-05-04 | 2023-03-31 | -0.83 | -0.92 | -0.09 | 10 | ||
2020-05-13 | 2020-03-31 | -0.67 | -0.78 | -0.11 | 16 | ||
2024-11-01 | 2024-09-30 | -0.98 | -0.8596 | 0.1204 | 12 | ||
2022-02-24 | 2021-12-31 | -0.87 | -1.01 | -0.14 | 16 | ||
2023-08-03 | 2023-06-30 | -0.83 | -0.98 | -0.15 | 18 | ||
2021-11-04 | 2021-09-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2021-02-25 | 2020-12-31 | -0.85 | -1.01 | -0.16 | 18 |
Know BridgeBio Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BridgeBio Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BridgeBio Pharma backward and forwards among themselves. BridgeBio Pharma's institutional investor refers to the entity that pools money to purchase BridgeBio Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pictet Asset Manangement Sa | 2024-06-30 | 2.6 M | Capital Research Global Investors | 2024-09-30 | 2.6 M | Alliancebernstein L.p. | 2024-06-30 | 2.5 M | Goldman Sachs Group Inc | 2024-06-30 | 2.3 M | Ensign Peak Advisors Inc | 2024-09-30 | 1.9 M | Sc Us (ttgp), Ltd. | 2024-06-30 | 1.9 M | Cormorant Asset Management, Llc | 2024-09-30 | 1.9 M | Fmr Inc | 2024-09-30 | 1.8 M | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.7 M | Kohlberg Kravis Roberts & Co Lp | 2024-06-30 | 31.1 M | Viking Global Investors Lp | 2024-09-30 | 25.1 M |
BridgeBio Pharma's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.2 B.Market Cap |
|
BridgeBio Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.51) | (1.58) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | 0.47 | 0.50 |
Determining BridgeBio Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if BridgeBio Pharma is a good buy. For example, gross profit margin measures BridgeBio Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BridgeBio Pharma's profitability and make more informed investment decisions.
Evaluate BridgeBio Pharma's management efficiency
BridgeBio Pharma has return on total asset (ROA) of (0.4888) % which means that it has lost $0.4888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8967) %, meaning that it created substantial loss on money invested by shareholders. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Equity is likely to grow to 0.50, while Return On Tangible Assets are likely to drop (1.30). At this time, BridgeBio Pharma's Total Assets are very stable compared to the past year. As of the 28th of November 2024, Non Current Assets Total is likely to grow to about 74.3 M, though Net Tangible Assets are likely to grow to (1.1 B).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (8.25) | (7.83) | |
| Tangible Book Value Per Share | (8.41) | (7.99) | |
| Enterprise Value Over EBITDA | (14.03) | (14.74) | |
| Price Book Value Ratio | (4.85) | (4.61) | |
| Enterprise Value Multiple | (14.03) | (14.74) | |
| Price Fair Value | (4.85) | (4.61) | |
| Enterprise Value | 7.9 B | 8.3 B |
The operational strategies employed by BridgeBio Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.086 |
Basic technical analysis of BridgeBio Stock
As of the 28th of November, BridgeBio Pharma shows the Risk Adjusted Performance of 0.0506, downside deviation of 2.88, and Mean Deviation of 2.75. BridgeBio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BridgeBio Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BridgeBio Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on BridgeBio Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BridgeBio Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BridgeBio Pharma's Outstanding Corporate Bonds
BridgeBio Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BridgeBio Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BridgeBio bonds can be classified according to their maturity, which is the date when BridgeBio Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US10806XAB82 Corp BondUS10806XAB82 | View |
Understand BridgeBio Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BridgeBio Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0506 | |||
| Market Risk Adjusted Performance | 0.1854 | |||
| Mean Deviation | 2.75 | |||
| Semi Deviation | 2.72 | |||
| Downside Deviation | 2.88 | |||
| Coefficient Of Variation | 1802.81 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.59 | |||
| Information Ratio | 0.0237 | |||
| Jensen Alpha | 0.0716 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0326 | |||
| Treynor Ratio | 0.1754 | |||
| Maximum Drawdown | 19.79 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 6.76 | |||
| Downside Variance | 8.27 | |||
| Semi Variance | 7.4 | |||
| Expected Short fall | (3.45) | |||
| Skewness | 1.59 | |||
| Kurtosis | 4.46 |
| Risk Adjusted Performance | 0.0506 | |||
| Market Risk Adjusted Performance | 0.1854 | |||
| Mean Deviation | 2.75 | |||
| Semi Deviation | 2.72 | |||
| Downside Deviation | 2.88 | |||
| Coefficient Of Variation | 1802.81 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.59 | |||
| Information Ratio | 0.0237 | |||
| Jensen Alpha | 0.0716 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0326 | |||
| Treynor Ratio | 0.1754 | |||
| Maximum Drawdown | 19.79 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 6.76 | |||
| Downside Variance | 8.27 | |||
| Semi Variance | 7.4 | |||
| Expected Short fall | (3.45) | |||
| Skewness | 1.59 | |||
| Kurtosis | 4.46 |
Consider BridgeBio Pharma's intraday indicators
BridgeBio Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BridgeBio Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BridgeBio Pharma Corporate Filings
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 6th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
BridgeBio Stock media impact
Far too much social signal, news, headlines, and media speculation about BridgeBio Pharma that are available to investors today. That information is available publicly through BridgeBio media outlets and privately through word of mouth or via BridgeBio internal channels. However, regardless of the origin, that massive amount of BridgeBio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BridgeBio Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BridgeBio Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BridgeBio Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BridgeBio Pharma alpha.
BridgeBio Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BridgeBio Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BridgeBio Pharma Historical Investor Sentiment
Investor biases related to BridgeBio Pharma's public news can be used to forecast risks associated with an investment in BridgeBio. The trend in average sentiment can be used to explain how an investor holding BridgeBio can time the market purely based on public headlines and social activities around BridgeBio Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BridgeBio Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BridgeBio Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average BridgeBio Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on BridgeBio Pharma.
BridgeBio Pharma Corporate Management
| Neil Kumar | President, CoFounder | Profile | |
| MBA CPC | Chief Officer | Profile | |
| Eli Wallace | Chief Oncology | Profile | |
| Frank McCormick | CoFounder Oncology | Profile | |
| Thomas Trimarchi | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between BridgeBio Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.